Asset-based health sciences and regenerative medicine company Cardium Therapeutics is focused on acquiring and strategically developing new and innovative biomedical product opportunities and businesses. The company acquires and develops opportunities and businesses that have the potential to address significant unmet medical needs with definable pathways to commercialization, partnering, and other economic monetizations.

Cardium’s business model has been designed to create multiple opportunities for success without relying on any single technology platform or product type, as well as to leverage the company’s skills in late-stage product development and bridge the gap between promising new technologies and commercialization-ready product opportunities. Cardium considers various corporate development transactions that are designed to place its product candidates into larger organizations and with partners that have existing commercialization, sales, and marketing resources and a need for innovative products. These transactions can involve the sale, partnering, or other monetization of specific product opportunities or businesses.

Within its medical opportunities portfolio, Cardium has four private company business units: LifeAgain Insurance Solutions, Inc., which recently announced its first term life insurance program for men with active localized prostate cancer; Angionetic Biologics, which includes the company’s late stage cardiovascular product candidate, Generx; Activation Therapeutics, which encompasses the company’s regenerative medicine wound healing technology platform, including Excellagen; and To Go Brands, which develops, markets and sells dietary supplements through established regional and national retailers.

For more information, visit Cardium’s website at www.cardiumthx.com

Let us hear your thoughts below: